API Import of Ensifentrine obtained from Indian Customs Trade Statistics

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Rpl-554, 298680-25-8, Rpl554, 1884461-72-6, Ensifentrine [inn], Ensifentrine [usan]
Molecular Formula
C26H31N5O4
Molecular Weight
477.6  g/mol
InChI Key
CSOBIBXVIYAXFM-UHFFFAOYSA-N
FDA UNII
3E3D8T1GIX

Ensifentrine
Ensifentrine is an inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. This may lead to bronchial smooth muscle relaxation and modulate inflammatory responses. PDE3 and PDE4, members of the PDE superfamily, hydrolyze cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates. PDE3 is the most expressed PDE isoenzyme in bronchial smooth muscle. PDE4 is expressed in immune cells including T-cells, monocytes, macrophages, neutrophils, dendritic cells and eosinophils. It plays an important role in inflammation, especially in inflammatory airway diseases.
1 2D Structure

Ensifentrine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea
2.1.2 InChI
InChI=1S/C26H31N5O4/c1-15-10-16(2)24(17(3)11-15)29-23-14-20-19-13-22(35-5)21(34-4)12-18(19)6-8-30(20)26(33)31(23)9-7-28-25(27)32/h10-14H,6-9H2,1-5H3,(H3,27,28,32)
2.1.3 InChI Key
CSOBIBXVIYAXFM-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2CCNC(=O)N)OC)OC)C
2.2 Other Identifiers
2.2.1 UNII
3E3D8T1GIX
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one

2. Rpl 554

3. Rpl-554

4. Rpl554

2.3.2 Depositor-Supplied Synonyms

1. Rpl-554

2. 298680-25-8

3. Rpl554

4. 1884461-72-6

5. Ensifentrine [inn]

6. Ensifentrine [usan]

7. Ls-193855

8. 3e3d8t1gix

9. Ls-193,855

10. A]isoquinolin-3(4h)-yl}ethyl)urea

11. (e)-1-(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2h-pyrimido[6,1-a]isoquinolin-3(4h)-yl)ethyl)urea

12. 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea

13. Trimethylphenyl)imino]-6,7-dihydro-2h-pyrimido[6,1-

14. N-(2-{(2e)-9,10-dimethoxy-4-oxo-2-[(2,4,6-

15. 2-(9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido(6,1-a)isoquinolin-3-yl)ethylurea

16. N-(2-((2e)-9,10-dimetoxi-4-oxo-2-((2,4,6-trimetilfenil)imino)-6,7-dihidro-2h-pirimido(6,1-a)isoquinolein-3(4h)-il)etil)urea

17. Urea, N-(2-(6,7-dihydro-9,10-dimethoxy-4-oxo-2-((2,4,6-trimethylphenyl)imino)-2h-pyrimido(6,1-a)isoquinolin-3(4h)-yl)ethyl)-

18. Unii-3e3d8t1gix

19. Vmx-554

20. Rpl-554;ensifentrinum

21. Ensifentrine (usan/inn)

22. Ensifentrine [who-dd]

23. Schembl625876

24. Chembl4594287

25. Schembl20720900

26. Gtpl11865

27. Dtxsid00183983

28. Bcp31840

29. Ex-a6633

30. Who 10726

31. Sb19810

32. D11743

33. A937318

34. Q7277486

35. Ensifentrina; Ensifentrinum;rpl-554;rpl554;rpl 554

36. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one

37. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one

38. 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one

39. 9,10-dimethoxy-2-(2.4.6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6.1-a]isoquinolin-4-one

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 477.6 g/mol
Molecular Formula C26H31N5O4
XLogP32.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass477.23760449 g/mol
Monoisotopic Mass477.23760449 g/mol
Topological Polar Surface Area110 Ų
Heavy Atom Count35
Formal Charge0
Complexity849
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content

Ensifentrine

About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...

Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. Neuland’s expertise is in the manufacturing of APIs and advanced intermediates from its USFDA-approved facilities. Its core competency lies in the application of powerful process chemistry to manufacturing in a regulatory-compliant environment.
Neuland

02

Seqens

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Flag France
Digital Content Digital Content

Ensifentrine

About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...

Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. It offers a large portfolio of APIs and proprietary products. Seqens also develops custom solutions and ingredients for the most demanding industries, such as healthcare, electronics and cosmetics. Its unique range of technologies enables it to manufacture complex molecules for small- and large-scale demands. It operates 24 industrial plants and 10 R&D centres across the globe.
Seqens Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.

Flag China
Digital Content Digital Content

Ensifentrine

About the Company : Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosyn...

Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosynthetic APIs (application contains oncology, nervous system, and metabolic diseases and etc.,) with a product portfolio ranging from small molecule APIs, ADC compounds (linkers and payloads) to polypeptides, also provides CDMO services of cytotoxic and OEB4/5 grade APIs.
Chongqing Sintaho Pharmaceutical

04

Angene International

United Kingdom
ASC 2024
Not Confirmed
arrow

Angene International

United Kingdom
arrow
ASC 2024
Not Confirmed

Ensifentrine

About the Company : Angene is pledged to providing quality chemicals for use in research and development and commercial manufacturing. Angenes offers over 100,000 products including lab reagents, inte...

Angene is pledged to providing quality chemicals for use in research and development and commercial manufacturing. Angenes offers over 100,000 products including lab reagents, intermediates, bulk commodities, agro-chemicals, natural ingredients and active pharmaceutical ingredients (APIs). In addition to the 100,000+ products, Angene offers custom synthesis of chemicals that are not commercially available.
blank

05

Chemicea

India
ASC 2024
Not Confirmed
arrow

Chemicea

India
arrow
ASC 2024
Not Confirmed

Ensifentrine

About the Company : Chemicea Pharmaceuticals is a reputable contract research organization based in Pune, India. Specializing in chemistry-driven solutions, Chemicea offers a wide range of R&D product...

Chemicea Pharmaceuticals is a reputable contract research organization based in Pune, India. Specializing in chemistry-driven solutions, Chemicea offers a wide range of R&D products and services tailored for Pharmaceutical/Biotech companies and research institutes. Certified under ISO 9001:2015, the company excels in providing pharmaceutical impurities such as Process Impurities, Degradation Impurities, API Intermediates, and Custom Synthesis. Their expertise lies in delivering high-quality solutions crucial for the development and production processes within the pharmaceutical industry.
blank

06

ASC 2024
Not Confirmed
arrow
arrow
ASC 2024
Not Confirmed

Ensifentrine

About the Company : Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With ...

Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With its fast and efficient synthesis, the Glixx R&D team focuses on commercializing newly discovered research chemicals and bringing them to the life sciences R&D communities. Our company goal is to help our community by lowering the cost of the essential chemicals for research needs, to better progress on to new discoveries in drug development, medical screening, and all facets of scientific innovations.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Ohtuvayre (ensifentrine), is a first-in-class PDE3/4 inhibitor product candidate, which is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ohtuvayre

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2024

blank

01

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : Ohtuvayre (ensifentrine), is a first-in-class PDE3/4 inhibitor product candidate, which is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease.

Brand Name : Ohtuvayre

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 26, 2024

blank

Details:

The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Oaktree Capital Management, L.P

Deal Size: $650.0 million Upfront Cash: Undisclosed

Deal Type: Financing May 09, 2024

blank

02

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Undisclosed

May 09, 2024

blank

Details:

The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Oxford Finance

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing January 02, 2024

blank

03

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : The proceeds will support Verona’s planned commercial launch of RPL554 (ensifentrine), Verona Pharma’s first-in-class product candidate, which is under review by the US FDA for the maintenance treatment of chronic obstructive pulmonary disease.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Undisclosed

January 02, 2024

blank

Details:

RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2023

blank

04

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 11, 2023

blank

Details:

RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 27, 2023

blank

05

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 27, 2023

blank

Details:

RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 10, 2023

blank

06

ASC 2024
Not Confirmed
ASC 2024
Not Confirmed

Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 10, 2023

blank

Details:

Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2023

blank

07

ASC 2024
Not Confirmed
ASC 2024
Not Confirmed

Details : Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 06, 2023

blank

Details:

Ensifentrine (RPL554) is an investigational, first-in-class, selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 that combines bronchodilator and anti-inflammatory activities in one compound.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 20, 2022

blank

08

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : Ensifentrine (RPL554) is an investigational, first-in-class, selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 that combines bronchodilator and anti-inflammatory activities in one compound.

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 20, 2022

blank

Details:

RPL554 (ensifentrine), met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 19, 2022

blank

09

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : RPL554 (ensifentrine), met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 19, 2022

blank

Details:

The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine (RPL554), the first-in-class product candidate, which reported positive Phase 3 data in the ENHANCE-2 trial in chronic obstructive pulmonary disease.


Lead Product(s): Ensifentrine

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RPL554

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Oxford Finance LLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing October 17, 2022

blank

10

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Verona Pharma

United Kingdom
arrow
ASC 2024
Not Confirmed

Details : The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine (RPL554), the first-in-class product candidate, which reported positive Phase 3 data in the ENHANCE-2 trial in chronic obstructi...

Brand Name : RPL554

Molecule Type : Small molecule

Upfront Cash : Undisclosed

October 17, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

VERONA PHARMA

United Kingdom
ASC 2024
Not Confirmed
arrow

VERONA PHARMA

United Kingdom
arrow
ASC 2024
Not Confirmed

ENSIFENTRINE

Brand Name : OHTUVAYRE

Dosage Form : SUSPENSION;INHALATION

Dosage Strength : 3MG/2.5ML

Approval Date : 2024-06-26

Application Number : 217389

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
ASC 2024
Not Confirmed

VERONA PHARMA

United Kingdom
arrow
ASC 2024
Not Confirmed

ENSIFENTRINE

US Patent Number : 10945950

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 217389

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-15

blank

02

arrow
ASC 2024
Not Confirmed

VERONA PHARMA

United Kingdom
arrow
ASC 2024
Not Confirmed

ENSIFENTRINE

US Patent Number : 9062047

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 217389

Patent Use Code : U-3962

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-08-21

blank

03

arrow
ASC 2024
Not Confirmed

VERONA PHARMA

United Kingdom
arrow
ASC 2024
Not Confirmed

ENSIFENTRINE

US Patent Number : 9956171

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 217389

Patent Use Code : U-3962

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-15

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty